The IEM mobile app runs on Android-based smartphones, but Savage said Proteus expects to have a version available for Apple's iOS next year. The company also expects to expand the range of applications that can work with the sensor to support different patient scenarios relating to specific therapeutic areas, patient living situations, or the population of customers using the sensor and digital medical system, he said.
Proteus already has run a number of clinical trials with the IEM in various populations and reports positive feedback, with "people seeing enormous value in what the technology can offer," Savage said. There have been some red flags raised over the potentially invasive nature of integrating a digital tracking device into a medication. Topol said that these concerns are "legitimate." The IEM is "an option and new emerging choice that will be out here for some patients and some circumstances."
Savage said inclusion in pills is certainly not the only use for the IEM or the rest of his company's digital medical system. "The technology platform can be used to create an array of different products for different customers," he said. "We expect most of the products to target people suffering from chronic illness and their support team -- family caregivers, clinicians, etc."
Proteus will launch the first commercial IEM and related digital health system in the UK this year. FDA approval has paved the way for use in the US in the near future.